![]() |
|
Supporting Organizations:
|
![]() |
![]() |
![]() |
![]() |
|
Gold Sponsor
Silver Sponsors
Bronze Sponsors
Media Partners
|
Congressman Mike Rogers
to deliver Keynote Address!
About the Event:
The threat of a significant influenza pandemic looms. In late 2005, President Bush outlined his $7B plan to prepare for a pandemic. The money is now being released to industry. On March 4, 2006, the Department of Health and Human Services awarded over $1B in contracts to five biopharmaceutical companies to drive new flu vaccine technologies. As a consequence, expectations for the country's pandemic preparedness are rising rapidly. However, delivering on pandemic influenza preparedness will require many additional steps, and the path forward is not yet clear.
End-to-End Preparedness for Pandemic Influenza: Opportunities for Public-Private Collaboration will bring together senior government officials and top industry executives to explore how an effective partnership between government and industry can be developed to tackle the next critical steps in delivering on public health preparedness for pandemic influenza. From development to production to supply to administration, these key leaders will examine each step in preparedness to identify the opportunities for strengthening government and industry collaboration and to address the underlying capabilities that must be in place to ensure success.
|
KEYNOTE SPEAKER:
Congressman (R-MI)
Featured Speakers:
Rear Admiral, United States Public Health Service; Assistant Surgeon General; Director, National Center for Immunization and Respiratory Diseases (proposed) CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC)
Franz Kracher, Participating Companies
ASD Healthcare Baxter Vaccines Centers for Disease Control and Prevention (CDC) Cardinal Health, Inc. Cornell University DC Department of Health Department of Health & Human Services (DHHS) FFF Enterprises, Inc. ImmuneRegen BioSciences, Inc. Implicit Bioscience Pty. Ltd. McKenna Long & Aldridge MedImmune, Inc. Novavax Inc. PRTM Management Consultants Punk, Ziegel & Company Roche Sanofi Pasteur SA Solvay Pharmaceuticals B.V. U.S. Food and Drug Administration (FDA) |